Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Neuroendocrine Neoplasm

National Cancer Institute (NCI)Small moleculePhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Neuroendocrine Neoplasm cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
National Cancer Institute (NCI)
Phase 2BB
Vinorelbine
Vanderbilt-Ingram Cancer Center
Phase 2BB
Epirubicin
University of Michigan Rogel Cancer Center
Phase 2B
Octreotide Pamoate
National Cancer Institute (NCI)
Phase 3B
INTERFERON ALFA-2B
National Cancer Institute (NCI)
Phase 3B

View all 11 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →